Chondroprotecfive agents, also known as structure-altering drugs, are drugs that can partially or completely block or relieve damage to articular cartilage in people with OA. At present, the following drugs are being used clinically in China: vitreonate injection, glucosamine, chondroitin sulfate, tetracycline family antibiotics, bisphosphonates, etc., especially the first 2 drugs are more commonly used. Sodium vitrate is an important component of the extracellular matrix in joint tissues, involved in the regulation of electrolytes and water in the extracellular fluid, involved in the process of articular cartilage trauma repair and electrification, lubricates joints, inhibits phagocyte wandering and phagocytosis, and obscures nociceptive receptors. Used in the early stages of OA, it has positive efficacy in relieving joint pain, increasing joint mobility, and eliminating synovial inflammation. The disadvantages are that intra-articular injection is required, the drug is expensive, and the efficacy cannot be maintained for a long time after discontinuation. d-Electroglycosamine is an aminohexose composed of keratin sulfate and hyaluronic acid. It stimulates chondrocytes to produce proteoglycans with normal multimeric structure, directly blocks the activity of various proteases and inhibits the production of peroxide residues by macrophages. It is used in the treatment of OA to help suppress the inflammatory response, prevent disease progression, and improve joint function. The disadvantage is that the onset of action is slow and requires prolonged use according to a course of treatment.